Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia

Haematologica

Volumn 93, Issue 12, 2008, Pages 1806-1813

  Malfuson, Jean Valère ^a   Etienne, Anne ^b   Turlure, Pascal ⁱ   De Revel, Thierry ^a   Thomas, Xavier ^d   Contentin, Nathalie ^e   Terré, Christine ^c,f   Rigaudeau, Sophie ^c,f   Bordessoule, Dominique ⁱ   Vey, Norbert ^b   Gardin, Claude ^g   Dombret, Hervé ^h  

^a PERCY MILITARY HOSPITAL   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e Centre Becquerel   (France)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

^g UNIVERSITÉ PARIS 13   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ Hôpital Saint Louis ^*

Author keywords

Acute myeloid leukemia; Decision criteria; Elderly; Prognosis; Risk factors

Indexed keywords

CYTARABINE; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; FALSE POSITIVE RESULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; INTENSIVE CARE; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOGENETIC ANALYSIS; DAUNORUBICIN; DECISION MAKING; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 57549098626     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13309     Document Type: Article

References (27)

1. Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia 2000;14:480-7.
2. Estey EH. How I treat older patients with AML. Blood 2004;96:1670-3.
3. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-5.
4. Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K, et al. Cytogenetics and age are the major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from the AMLSG trial AML HD98-B. Blood 2006;108:3280-8.
5. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from cancer and leukemia group B 8461. Cancer and Leukemia Group B 8461. Blood 2006;108:63-73.
6. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25:1908-15.
7. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2006;106:1090-8.
8. Sorror ML, Marris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Stoner B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-9.
9. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007;136:624-7.
10. Etienne A, Esterni B, Charbonnier A, Mozziconacci MJ, Arnoulet C, Coso D, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007;09:1376-83.
11. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, et al. Post-remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy - Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007;109:5129-35.
12. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-24.
13. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. International Working Group for diagnosis, dtandardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972;135:185-206.
16. Hilsenbeck SG, Clark GM. Practical P-value adjustment for optimally selected cut-points. Stat Med 1996;15:103-12.
17. Deschler B, de Witte T, Mertelsmann R, Lübbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006; 91:1513-22.
18. Sekeres M, Elson P, Wang X. Time from Diagnosis to treatment initiation predicts survival in acute myeloid leukemia (AML). Blood (ASH Annual Meeting Abstracts), Nov 2007;110:598[Abstract].
19. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Medical Research Council Adult Leukemia Working Party. Blood 2001;98:1312-20.
20. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-85.
21. Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Br J Haematol 2007;136: 96-105.
22. Terré C, Gardin, C, Gachard N. Prognostic impact of cytogenetic abnormalities in elderly patients with acute myeloid leukemia (AML) enrolled in the ALFA-9803 trial. Blood (ASH Annual Meeting Abstracts) 2007;110:4233.
23. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004;18:115-36.
24. Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007;21:1937-44.
25. Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007;25:25-31.
26. Burnett AK, Baccarani M, Johnson P, Yin J, Saunders A, Russell N, Hills RK. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable (ASH Annual Meeting Abstracts). Blood 2006;108:130a[Abstract].
27. Erba HP, Kantarjian HM, Claxton D. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy (ASCO Annual Meeting Abstracts). J Clin Oncol 2008:26[Abstract 7025].